KAREN RABIN to Neoplasm, Residual
This is a "connection" page, showing publications KAREN RABIN has written about Neoplasm, Residual.
Connection Strength
0.758
-
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. J Clin Oncol. 2024 Jan 10; 42(2):218-227.
Score: 0.198
-
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 04; 68(4):e28929.
Score: 0.164
-
Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020 07; 34(7):1741-1750.
Score: 0.153
-
Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia. EBioMedicine. 2019 Oct; 48:49-57.
Score: 0.149
-
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood. 2023 12 14; 142(24):2069-2078.
Score: 0.050
-
Residence in a Latinx enclave and end-induction minimal residual disease positivity among children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2022 Oct; 39(7):650-657.
Score: 0.044